President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

Johnson & Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma earnings on Wednesday, with investors focusing on ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...

U.S. President Donald Trump on Tuesday indicated that the United States is likely to impose tariffs on imported ...

Tariff Threats Prompt Expedited Pharmaceutical Shipments to U.S. March 27, 2025. Some drugmakers ... Pharmaceutical products have long been spared from trade wars due to the potential harms.